The stock of Edgewise Therapeutics Inc (EWTX) has seen a 3.68% increase in the past week, with a 25.55% gain in the past month, and a 0.96% flourish in the past quarter. The volatility ratio for the week is 6.51%, and the volatility levels for the past 30 days are at 6.96% for EWTX. The simple moving average for the past 20 days is 15.43% for EWTX’s stock, with a 80.74% simple moving average for the past 200 days.
Is It Worth Investing in Edgewise Therapeutics Inc (NASDAQ: EWTX) Right Now?
The 36-month beta value for EWTX is also noteworthy at 0.19. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for EWTX is 62.94M, and at present, short sellers hold a 9.16% of that float. The average trading volume of EWTX on May 10, 2024 was 735.58K shares.
EWTX) stock’s latest price update
Edgewise Therapeutics Inc (NASDAQ: EWTX)’s stock price has plunge by -4.26relation to previous closing price of 20.89. Nevertheless, the company has seen a 3.68% surge in its stock price over the last five trading sessions. Zacks Investment Research reported 2024-02-26 that The consensus price target hints at a 52.8% upside potential for Edgewise Therapeutics, Inc. (EWTX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Analysts’ Opinion of EWTX
Many brokerage firms have already submitted their reports for EWTX stocks, with Piper Sandler repeating the rating for EWTX by listing it as a “Overweight.” The predicted price for EWTX in the upcoming period, according to Piper Sandler is $48 based on the research report published on March 07, 2024 of the current year 2024.
Goldman gave a rating of “Sell” to EWTX, setting the target price at $5 in the report published on August 25th of the previous year.
EWTX Trading at 16.88% from the 50-Day Moving Average
After a stumble in the market that brought EWTX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -7.41% of loss for the given period.
Volatility was left at 6.96%, however, over the last 30 days, the volatility rate increased by 6.51%, as shares surge +21.29% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +20.12% upper at present.
During the last 5 trading sessions, EWTX rose by +3.68%, which changed the moving average for the period of 200-days by +186.12% in comparison to the 20-day moving average, which settled at $17.50. In addition, Edgewise Therapeutics Inc saw 82.82% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at EWTX starting from Donovan Joanne M., who sale 3,682 shares at the price of $18.91 back on May 02 ’24. After this action, Donovan Joanne M. now owns 19,897 shares of Edgewise Therapeutics Inc, valued at $69,627 using the latest closing price.
KOCH KEVIN, the President and CEO of Edgewise Therapeutics Inc, sale 3,152 shares at $18.91 during a trade that took place back on May 02 ’24, which means that KOCH KEVIN is holding 14,478 shares at $59,604 based on the most recent closing price.
Stock Fundamentals for EWTX
The total capital return value is set at -0.35. Equity return is now at value -30.10, with -28.33 for asset returns.
Based on Edgewise Therapeutics Inc (EWTX), the company’s capital structure generated 0.02 points at debt to capital in total, while cash flow to debt ratio is standing at -16.98. The debt to equity ratio resting at 0.02. The interest coverage ratio of the stock is 36.81.
Currently, EBITDA for the company is -112.62 million with net debt to EBITDA at 0.71. The liquidity ratio also appears to be rather interesting for investors as it stands at 19.50.
Conclusion
In summary, Edgewise Therapeutics Inc (EWTX) has had a better performance as of late. Analysts have mixed opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
